Sigilon Therapeutics’ mission is to create immune-protected, engineered human cells that restore normal physiology in a wide range of diseases without generating fibrosis or immune rejection, liberating patients from challenges associated with serious chronic diseases. 

Biotechnology

Sigilon Therapeutics

Rogerio Vivaldi

Eric Shaff

Michael Owings

Jillian Higgins

Marylou Ross

Omid Veiseh

Jamie M.

Jamie Murphy

Sarah Yuan

Joseph Tumang

Olivia G. Kelly

Jiang Wu

Philip Ashton-Rickardt

Leadership Team

Administration and Executive Management

Scientific and Research Team

Advisors Team

Finance and Quality Team

Teams at Sigilon Therapeutics

Leadership Team

Administration and Executive Management

Scientific and Research Team

Advisors Team

Finance and Quality Team